selexipag has been researched along with Heart-Failure* in 2 studies
1 trial(s) available for selexipag and Heart-Failure
| Article | Year |
|---|---|
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH-targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the GRIPHON study.. Selexipag reduces the risk of a morbidity/mortality event vs. placebo irrespective of patient comorbidity status, suggesting that comorbidity status does not influence the treatment effect of selexipag. Topics: Acetamides; Antihypertensive Agents; Comorbidity; Double-Blind Method; Heart Failure; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
1 other study(ies) available for selexipag and Heart-Failure
| Article | Year |
|---|---|
Selexipag and the pulmonary hypertension continuum.
Topics: Acetamides; Heart Failure; Humans; Hypertension, Pulmonary; Pyrazines | 2022 |